Ind-Swift Limited

INDSWFTLTD

INE788B01028

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:50 31/05/2024 BST			5-day change	1st Jan Change
21.24 ^INR	-1.98%		-5.89%	+18.79%

05-14	Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI
05-14	Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	CI

Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024

May 14, 2024 at 03:08 pm

Ind-Swift Limited reported earnings results for the fourth quarter ended March 31, 2024. For the fourth quarter, the company reported sales was INR 1,352.33 million compared to INR 1,058.79 million a year ago. Revenue was INR 1,818.23 million compared to INR 1,121.58 million a year ago.

Net income was INR 375.4 million compared to INR 530.96 million a year ago. Basic earnings per share from continuing operations was INR 6.93 compared to INR 9.8 a year ago. Diluted earnings per share from continuing operations was INR 6.93 compared to INR 9.8 a year ago.

Latest news about Ind-Swift Limited

Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2024	05-14	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024	05-14	CI
Ind-Swift Limited Approves Execution of Loan Facility Agreement	03-30	CI
Ind-Swift Limited Announces Cessation of Sri Prakash Sharma as Independent Director, Effective March 31, 2024	03-30	CI
Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director	03-06	CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-09	CI
Ind-Swift Laboratories Limited agreed to acquire Ind-Swift Limited.	24/09/23	CI
Ind-Swift Gets Board Nod to Secure INR6 Billion Loan from Ind-Swift Laboratories	06/09/23	MT
The Office of the Regional P.F. Commissioner -Ii Dmg Regional Office, Karnal Imposed Damages and Interests on Ind-Swift Limited	23/08/23	CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	10/08/23	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2023	30/05/23	CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2023	30/05/23	CI
Ind-Swift Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Ind-Swift Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	14/11/22	CI
Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director	22/09/22	CI
Ind-Swift Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	09/08/22	CI
Ind-Swift Launches Products in Qatar	03/06/22	MT
Ind-Swift Limited Launches Finished Dosages Products	03/06/22	CI
Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer	30/05/22	CI
Ind-Swift Limited Reports Earnings Results for the Full Year Ended March 31, 2022	30/05/22	CI
Ind-Swift Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	30/05/22	CI
Ind-Swift Forms New Subsidiary in Kenya	16/05/22	MT
Ind-Swift Ltd. Announces Demise of Jatendar Kumar Kakkar, Non-Executive Independent Director	26/03/22	CI
Ind-Swift Limited Announces the Resignation of Amrender Kumar Yadav as Company Secretary & Compliance Officer	26/02/22	CI
Ind-Swift Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	14/02/22	CI

Chart Ind-Swift Limited

Duration

Period

More charts

Company Profile

Ind Swift Limited is an India-based pharmaceutical manufacturing and marketing company. The Company operates in both domestic and export markets. It is primarily engaged in the finished goods dosage and active pharmaceutical ingredients (APIs) and herbal products. The Company is also engaged in the hand sanitizer, face mask and personal protective equipment (PPE) kit market. It operates through various divisions, such as Noble Division, Nova Division, Ethical Division, Generic Division, Institution Division and Proposed Division. Its Noble Division produces various products, such as Zoxiclav, Glypar, Olmiswif, Telhim, Ozodom-DSR, Cefextil-O, Swiclo-Sp, Swifix-O, Swifix 200, Stemin and Stemin Forte. The Company also provides a range of COVID19 products, including masks, travel kits, hand sanitizers, and gloves. It has also launched two products, Stevia (natural sweetener) and Hangover (helps avoid alcoholic hangover). The Company also has five plants in India.

Sector

Pharmaceuticals

Calendar

11/08/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IND-SWIFT LIMITED	+18.79%	13.78M
ELI LILLY AND COMPANY	+40.73%	739B
NOVO NORDISK A/S	+32.83%	598B
JOHNSON & JOHNSON	-6.30%	353B
MERCK & CO., INC.	+15.15%	318B
ABBVIE INC.	+4.05%	285B
ASTRAZENECA PLC	+15.00%	240B
ROCHE HOLDING AG	-5.52%	206B
AMGEN INC.	+6.17%	164B
PFIZER, INC.	-0.45%	162B